The discontinuation of IMpactMF removes a major pipeline catalyst and makes Geron a single-product company dependent on LR-MDS. Watch for Q4 2026 revenue trajectory to assess whether the mid-to-high end of guidance is achievable, and monitor European launch execution and any pipeline re-evaluation.
Drug in focus
GERN drug pipeline →RYTELO
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available (first commercial launch in Q3 2024)
- Next catalyst
- None dated
What to watchWatch the Q3 2026 earnings release on Nov 4, 2026 (consensus ~$60.4M revenue). The key question is whether RYTELO's revenue growth trajectory can accelerate from the ~11% QoQ pace, which would validate the revenue ramp thesis behind the $4+ analyst targets. The 7.39 days-to-cover short interest adds a squeeze potential if results surprise positively, but the shareholder lawsuit and high short volume ratio suggest significant skepticism about the commercial ramp.
Price Chart
Executive Summary
Geron reported Q3 2026 RYTELO net product revenue of $60.1M, up 27% YoY from $47.2M, and achieved net income of $1.4M vs a net loss of $18.4M a year ago. The company reiterated 2026 RYTELO revenue guidance at the mid-to-high end of $220M-$240M and lowered operating expense guidance to $220M-$230M. However, the Phase 3 IMpactMF trial in myelofibrosis was discontinued after a DMC recommendation that it was unlikely to meet the overall survival endpoint, eliminating a key pipeline catalyst and increasing dependence on the LR-MDS indication.
Key Financial Metrics
Key Facts
- Q3 2026 RYTELO net product revenue $60.1M, up 27% YoY from $47.2M and up 5% QoQ from Q2 2026
- Net income of $1.4M in Q3 2026 vs net loss of $18.4M in Q3 2025
- Total costs and operating expenses decreased to $54.4M from $61.1M YoY
- 2026 RYTELO revenue guidance reiterated at mid-to-high end of $220M-$240M range
- 2026 total operating expense guidance lowered to $220M-$230M from prior $230M-$240M
- Phase 3 IMpactMF trial in JAK inhibitor R/R myelofibrosis discontinued after DMC recommendation that it was unlikely to meet the primary endpoint of overall survival
- Cash, cash equivalents, restricted cash and marketable securities of $339.4M as of September 30, 2026
- Initiated gated commercial launch in targeted European markets, with Germany expected by end of 2026
Financial Impact
Q3 revenue $60.1M, net income $1.4M, cash $339.4M
Risk Factors
- Phase 3 IMpactMF trial discontinued, no approval pathway for imetelstat in myelofibrosis
- Company increasingly dependent on single indication (LR-MDS) for revenue
- European commercial launch carries execution risk and reliance on third parties
- Cash burn continues; cash of $339.4M may require future financing if revenue growth slows
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-446203 |
| Document: d188608d8k.htm | 0001193125-26-446203 |
| Document: 0001193125-26-446203-index-headers.html | 0001193125-26-446203 |
| Document: 0001193125-26-446203-index.html | 0001193125-26-446203 |
| Document: 0001193125-26-446203.txt | 0001193125-26-446203 |
| 8-K Data (Synthetic) | 0001193125-26-446203 |
Track record
11 reports on GERN
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $0.9742 Now $0.9400 −3.51% settles Nov 17
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $0.9965 to $0.9419 Now $0.9400 −5.67% ▼ −5.48% −3.79% vs SPY
- Nov 4, 202612d ago 8-K Mixed 6/10 Viewing No price data
- Nov 4, 202612d ago Press Release Mixed 6/10 Entry $1.08 to $1.02 Now $0.9400 −12.96% ▼ −5.56% −4.64% vs SPY
- Oct 28, 202619d ago 8-K Bearish 6/10 Entry $0.9462 to $0.9501 Now $0.9400 +0.66% ▼ −0.41% −5.14% vs SPY
- Oct 19, 202628d ago Press Release Neutral 2/10 Entry $1.24 to $1.16 Now $0.9400 −24.19% ▼ −6.85% −6.88% vs SPY
- Sep 18, 20268w ago Press Release Neutral 2/10 Entry $1.30 to $1.25 Now $0.9400 −27.69% ▼ −3.85% −2.83% vs SPY
- Apr 22, 202629w ago Press Release Neutral 1/10 Entry $1.55 to $1.52 Now $0.9400 −39.35% ▼ −2.26% −2.31% vs SPY
- Apr 7, 202631w ago DEFA14A Neutral 3/10 Entry $1.71 to $1.69 Now $0.9400 −45.03% ▼ −1.17% −4.69% vs SPY
- Mar 30, 202633w ago Court Ruling Neutral 2/10 Entry $1.41 to $1.74 Now $0.9400 −33.33% ▲ +23.40% +19.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers